CGON Operating Cycle from 2010 to 2026
| CGON Stock | 55.21 1.34 2.49% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 225.25 | Current Value 198.8 | Quarterly Volatility 157.49151425 |
Check CG Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CG Oncology's main balance sheet or income statement drivers, such as Net Interest Income of 32.1 M, Depreciation And Amortization of 20.4 K or Interest Expense of 8.3 M, as well as many indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.0 or PTB Ratio of 2.67. CGON financial statements analysis is a perfect complement when working with CG Oncology Valuation or Volatility modules.
CGON | Operating Cycle | Build AI portfolio with CGON Stock |
Evaluating CG Oncology's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into CG Oncology Common's fundamental strength.
Latest CG Oncology's Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of CG Oncology Common over the last few years. It is CG Oncology's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CG Oncology's overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
CGON Operating Cycle Regression Statistics
| Arithmetic Mean | 83.46 | |
| Geometric Mean | 0.78 | |
| Coefficient Of Variation | 188.70 | |
| Mean Deviation | 117.73 | |
| Median | 0.07 | |
| Standard Deviation | 157.49 | |
| Sample Variance | 24,804 | |
| Range | 579 | |
| R-Value | 0.61 | |
| Mean Square Error | 16,501 | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | 19.13 | |
| Total Sum of Squares | 396,857 |
CGON Operating Cycle History
About CG Oncology Financial Statements
CG Oncology investors utilize fundamental indicators, such as Operating Cycle, to predict how CGON Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 225.25 | 198.80 |
Pair Trading with CG Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CG Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with CGON Stock
Moving against CGON Stock
| 0.62 | OSE | OSE Pharma SA | PairCorr |
| 0.61 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.47 | RAC | Race Oncology Earnings Call This Week | PairCorr |
| 0.46 | VCYT | Veracyte Earnings Call This Week | PairCorr |
| 0.43 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to CG Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CG Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CG Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CG Oncology Common to buy it.
The correlation of CG Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CG Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CG Oncology Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CG Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of CG Oncology Correlation against competitors. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Will Biotechnology sector continue expanding? Could CGON diversify its offerings? Factors like these will boost the valuation of CG Oncology. Projected growth potential of CGON fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CG Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.05) | Revenue Per Share | Quarterly Revenue Growth 37.744 | Return On Assets | Return On Equity |
Investors evaluate CG Oncology Common using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CG Oncology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause CG Oncology's market price to deviate significantly from intrinsic value.
It's important to distinguish between CG Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CG Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CG Oncology's market price signifies the transaction level at which participants voluntarily complete trades.